P. R. Herzig & Company bought a new position in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 34,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,101,000. Pfizer comprises 2.7% of P. R. Herzig & Company’s holdings, making the stock its 15th largest position.

A number of other hedge funds have also added to or reduced their stakes in the company. Lowe FS raised its stake in Pfizer by 54.9% in the third quarter. Lowe FS now owns 734 shares of the biopharmaceutical company’s stock worth $23,000 after buying an additional 260 shares in the last quarter. Taylor Wealth Management Partners boosted its position in shares of Pfizer by 4.3% in the fourth quarter. Taylor Wealth Management Partners now owns 2,555 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 105 shares in the last quarter. Lincoln Capital boosted its position in shares of Pfizer by 5.7% in the fourth quarter. Lincoln Capital now owns 8,316 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 446 shares in the last quarter. Vicus Capital boosted its position in shares of Pfizer by 17.6% in the fourth quarter. Vicus Capital now owns 8,547 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 1,282 shares in the last quarter. Finally, First Hawaiian Bank boosted its position in shares of Pfizer by 4.9% in the fourth quarter. First Hawaiian Bank now owns 9,140 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 429 shares in the last quarter.

Pfizer Inc. (NYSE:PFE) opened at 30.71 on Monday. Pfizer Inc. has a 52 week low of $28.47 and a 52 week high of $36.46. The firm has a market cap of $189.57 billion and a price-to-earnings ratio of 23.06. The company has a 50-day moving average of $31.87 and a 200-day moving average of $33.24.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.09. The company had revenue of $12.10 billion for the quarter, compared to the consensus estimate of $11.56 billion. During the same period in the prior year, the company earned $0.57 earnings per share. The firm’s revenue was down 2.2% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post $2.18 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 2nd. Investors of record on Friday, February 5th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.91%. This is an increase from Pfizer’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, February 3rd.

A number of equities analysts have recently weighed in on PFE shares. Jefferies Group lifted their price target on shares of Pfizer to $48.00 and gave the stock a “buy” rating in a research report on Monday, December 7th. Vetr raised shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.47 price target on the stock in a research report on Tuesday, October 6th. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $35.00 to $38.00 in a research report on Friday, October 2nd. Cowen and Company raised shares of Pfizer from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $25.00 to $43.00 in a research report on Tuesday, October 20th. Finally, Atlantic Securities started coverage on shares of Pfizer in a research report on Friday, December 18th. They set an “overweight” rating and a $39.00 price target on the stock. Six research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $39.83.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

12 Month Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.